ArticleFrontiers in immunology2024

Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals.

Alejandro Torres-Flores et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.